Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis  

作　　者：Minghui Li Weihua Cao Tingting Jiang Wen Deng Shiyu Wang Shuling Wu Lu Zhang Yao Lu Min Chang Ruyu Liu Xiaoyan Ding Ge Shen Yuanjiao Gao Hongxiao Hao Xiaoxue Chen Leiping Hu Mengjiao Xu Yuyong Jiang Wei Yi Yao Xie Rui Song 

机构地区：[1]Department of Hepatology Division 2,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [2]Department of Hepatology Division 2,Peking University Ditan Teaching Hospital,Beijing 100015,China [3]Department of Medical Oncology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [4]Center of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [5]Department of Gynecology and Obstetrics,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [6]Department of Infectious Disease,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

出　　处：《Biosafety and Health》2024年第3期165-170,共6页生物安全与健康（英文）

基　　金：the National Key Research and Development Program(2022YFC2603500,2022YFC2603505);Beijing Municipal Health Commission high-level public health technical personnel construction project,discipline leader-03-26,Beijing Hospitals Authority Clinical medicine Development of special funding support(XMLX 202127);the capital health research and development of special public health project(2022-1-2172);The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority(XXZ0302).

摘　　要：To explore the impact of ursodeoxycholic acid(UDCA)on severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection and clinical outcomes in patients with autoimmune liver disease(AILD).Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment.Relevant data were collected regarding AILD diagnosis,treatment,biochemical indicators,and imaging examination.The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed.A total of 1,138 patients completed follow-up.The usage rate of hormone(P=0.003)and immunosuppressant(P=0.001)used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group.The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients(P=0.003).The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group(P=0.018).Logistic regression analysis showed that UDCA use(P=0.003)was correlated to a lower incidence of SARS-CoV-2,while immunosuppressant use(P=0.017)increased the incidence.Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group(P=0.018).UDCA is associated with low SARS-CoV-2 incidence in AILD patients,while immunosuppressant increases its incidence instead.Patients receiving UDCA treatment have a longer recovery time after being infected.

关 键 词：Ursodeoxycholic acid(UDCA) Autoimmune liver disease(AILD) Coronavirus disease 2019(COVID-19) Primary biliary cholangitis(PBC) Autoimmune hepatitis(AIH) 

分 类 号：R511[医药卫生—内科学] R575[医药卫生—临床医学]